Research
Hormonal
Tirzepatide improves renal outcomes, including reducing the risk of macroalbuminuria and slowing the decline in estimated glomerular filtration rate (eGFR), in patients with Type 2 Diabetes.
If you have Type 2 Diabetes and are concerned about kidney health, tirzepatide not only helps control blood sugar and weight but also offers significant protection for your kidneys, reducing the risk of serious renal complications compared to insulin therapy.
GoodSupportsHIGH confidence
Tirzepatide significantly slowed the decline in estimated glomerular filtration rate (eGFR) and clinically significantly reduced the albumin/creatinine ratio... The frequency of the combined renal endpoint... was 42% lower in the tirzepatide group.
Why this rating
Based on a sub-analysis of a large RCT (SURPASS-4), showing consistent positive trends.
Source
New horizons in the management of metabolic diseases: Focus on the efficacy and safety of tirzepatide
T. Yu. Demidova et al. · FOCUS Endocrinology · 2025
DOI 10.62751/2713-0177-2025-6-3-03
narrative_reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly improves glycemic control and reduces body weight in patients with type 2 diabetes compared to placebo, other GLP-1 agonists, and insulin.Strong
- Tirzepatide reduces liver fat content and visceral adipose tissue in patients with Type 2 Diabetes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →